title: [The hypertensive type II diabetic patient treated with captopril in free general practice (Austrian Safety Study). An indications study].
abstract: In 826 hypertensive patients including 396 with non-insulin dependent diabetes mellitus safety and efficacy of captopril 50 mg per day was evaluated throughout three months. In all patients blood pressure was significantly reduced. Moreover, in part of the patients with microalbuminuria, these tests turned negative with treatment. In addition, in patients with diabetes fasting and postprandial plasma glucose levels as well as HBA1C levels decreased. Only in 6.8% side effects occurred. In all patients quality of life as evaluated by a 10 item rating scale questionnaire improved. Taken together the results of this observational study confirm improvement of blood pressure levels, kidney function and metabolic derangements in diabetic patients treated with the ACE-inhibitor captopril. Effectiveness of these actions of captopril in respect to longterm prognosis in diabetics, however, remains to be established.
authors.affiliation: Klinischen Abteilung für Kardiologie, Universitätsklinik für Innere Medizin II, Wien.
authors.forename: B
authors.initials: B
authors.lastname: Stanek
authors.forename: E
authors.initials: E
authors.lastname: Basalka
authors.forename: K
authors.initials: K
authors.lastname: Seitl
authors.forename: I
authors.initials: I
authors.lastname: Fiser
mesh_terms: D000368:Aged; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002216:Captopril / Q000009:adverse effects / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011358:Product Surveillance, Postmarketing; D011788:Quality of Life; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D002216:Captopril